1. RGNX will host a conference call on May 12, 2025. 2. Discussion will cover Q1 financial results and operational highlights. 3. RGNX's pipeline includes multiple therapies for rare diseases. 4. The company has advanced gene therapy since its founding in 2009. 5. Thousands have been treated using REGENXBIO's gene therapy platform.
The upcoming conference call may reveal strong Q1 performance, which can enhance investor confidence. Historical precedent shows that such calls often lead to price jumps if results exceed expectations.
The article details critical financial information that could lead to a positive reassessment of RGNX's value. The announcements and outcomes from the call are pivotal for current and prospective investors.
The timing of the conference call is imminent, creating immediate investor interest. Historically, stock price movements occur in response to quarterly earnings announcements.
ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Dana Cormack
Corporate Communications
[email protected]
Investors:
George E. MacDougall
Investor Relations
[email protected]
SOURCE REGENXBIO Inc.